InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces ‘Key Transition’ Focused on Sale, Installation, Qualification of BaroFold Manufacturing System

Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmeceuticals, food and beverage, and other industries, is making an adjustment in its business approach. The company has announced “a key transition in its collaborations with multiple leaders and innovators in global biopharmaceutical development and commercialization, including preeminent Contract Development and Manufacturing Organizations (‘CDMOs).” According to the announcement, PBIO has graduated from serial product development and demonstration research contracts and taken a “pivotal leap forward” into the sale, installation and qualification of a research level BaroFold(TM) Protein Refolding Process Development System. The company noted that the first of these systems is being prepared for shipment to the main R&D site of a leading global CDMO.

“The purchase of a BaroFold System by a leading CDMO is expected to evolve into the commercial scale-up phase, eventually requiring the purchase of one or more custom-made BaroFold Commercial Scale Manufacturing Systems,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We estimate that each BaroFold Manufacturing System would likely generate millions of dollars in contract design, installation and qualification contracts for PBIO. Moreover, adoption of the BaroFold platform by CDMOs throughout their multisite organizations would accelerate the demonstration and adoption of BaroFold processing by the CDMO’s many biopharmaceutical company clients. As each biopharma client becomes ready to scale up further, we will support the establishment of BaroFold manufacturing sites under expanded licensing and contracting engagements. We anticipate the various BaroFold platform systems and the ongoing utilization and support fees associated with installations could eventually grow into annual revenue exceeding $100 million for PBIO.”

To view the full press release, visit https://ibn.fm/XmOo1

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Its patented enabling technology platform — Pressure Cycling Technology (“PCT”) — uses alternating cycles of pressure to control biomolecular interactions, such as cell lysis and biomolecule extraction, safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterrorism applications. PBIO has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room-temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.